European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“We’re excited to share two major early milestones for VIGOR (EORTC – 2427 – BTG), our new Phase III study in IDH – mutant astrocytoma: the first site has been activated and the first patient has already been randomised.
VIGOR evaluates vorasidenib as maintenance therapy following chemoradiotherapy, aiming to improve long – term outcomes for patients with IDH – mutant glioma WHO CNS Grade 2 or 3 astrocytoma.
Coordinated by EORTC with global partners, this trial represents a strong international effort to advance treatment options in brain cancer.
A special thank – you to the study coordinators Prof. Matthias Preusser and Dr. Marjolein Geurts for their leadership and commitment to advancing treatment options in neuro – oncology.”
More posts featuring European Organisation for Research and Treatment of Cancer